Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
Isambert N, Delord JP, Soria JC, Hollebecque A, Gomez-Roca C, Purcea D, Rouits E, Belli R, Fumoleau P. Isambert N, et al. Among authors: fumoleau p. Ann Oncol. 2015 May;26(5):1005-1011. doi: 10.1093/annonc/mdv031. Epub 2015 Feb 2. Ann Oncol. 2015. PMID: 25646368 Free article. Clinical Trial.
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosis.
Molucon-Chabrot C, Isambert N, Benoit L, Zanetta S, Fraisse J, Guilland JC, Royer B, Monin-Baroille P, Flesch M, Fargeot P, Coudert B, Mayer F, Fumoleau P, Chauffert B. Molucon-Chabrot C, et al. Among authors: fumoleau p. Anticancer Drugs. 2006 Nov;17(10):1211-7. doi: 10.1097/01.cad.0000236309.66080.3b. Anticancer Drugs. 2006. PMID: 17075321 Clinical Trial.
[Targeting ErbB receptors in breast cancer].
Fumoleau P, Campone M, Coudert B, Mayer F, Favier L, Ferrant E. Fumoleau P, et al. Bull Cancer. 2007;94(7 Suppl):F147-70. Bull Cancer. 2007. PMID: 17964992 Review. French.
[Angiogenesis targeting in breast cancer].
Fumoleau P, Coudert B, Mayer F, Isambert N, Favier L, Ferrant E. Fumoleau P, et al. Bull Cancer. 2007;94(7 Suppl):F199-206. Bull Cancer. 2007. PMID: 17964997 Review. French.
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme.
Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, Rampling R, Sorio R, Lacombe D, de Balincourt C, Fumoleau P; European Organisation for Research and Treatment of Cancer-Early Clinical Studies Group/New Drug Development Programme. Twelves C, et al. Among authors: fumoleau p. Ann Oncol. 2002 May;13(5):777-80. doi: 10.1093/annonc/mdf121. Ann Oncol. 2002. PMID: 12075748 Free article. Clinical Trial.
Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial.
Coudert BP, Arnould L, Moreau L, Chollet P, Weber B, Vanlemmens L, Moluçon C, Tubiana N, Causeret S, Misset JL, Feutray S, Mery-Mignard D, Garnier J, Fumoleau P. Coudert BP, et al. Among authors: fumoleau p. Ann Oncol. 2006 Mar;17(3):409-14. doi: 10.1093/annonc/mdj096. Epub 2005 Dec 6. Ann Oncol. 2006. PMID: 16332965 Free article. Clinical Trial.
Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.
Isambert N, Campone M, Bourbouloux E, Drouin M, Major A, Yin W, Loadman P, Capizzi R, Grieshaber C, Fumoleau P. Isambert N, et al. Among authors: fumoleau p. Eur J Cancer. 2010 Mar;46(4):729-34. doi: 10.1016/j.ejca.2009.12.005. Epub 2009 Dec 22. Eur J Cancer. 2010. PMID: 20031390 Clinical Trial.
280 results